Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Study to Compare Capecitabine + Bevacizumab Concomitantly With Radiotherapy Versus Capecitabine Concomitantly With Radiotherapy, as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer

NCT01043484 is registered in ClinicalTrials.gov with Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) as lead sponsor.

NCT NCT01043484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01043484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Study to Compare Capecitabine + Bevacizumab Concomitantly With Radiotherapy Versus Capecitabine Concomitantly With Radiotherapy, as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer
Lead sponsor
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
August 31, 2016
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer